StemCell Therapy

March 1, 2017 Patients with fatty liver disease may need a more intense dose of exercise. Credit: University of Queensland

Short bursts of high-intensity exercise could help people with non-alcoholic fatty liver disease reduce their risk of type 2 diabetes.

A trial led by University of Queensland School of Human Movement and Nutrition Sciences researcher Dr Shelley Keating will investigate if high intensity interval training (HIIT) can improve insulin sensitivity, fitness and other cardiovascular disease risk factors.

"Other than weight loss, there is no accepted therapy for improving non-alcoholic steatohepatitis (NASH) a type of fatty liver disease which is strongly linked to type 2 diabetes and cardiovascular disease," Dr Keating said.

"We have recently demonstrated that exercise therapy reduces liver fat in adults with obesity, but patients with NASH may need a more intense 'dose' of exercise.

"We hope to establish that high-intensity exercise is a safe, feasible and effective therapy for improving insulin resistance and other cardio-metabolic risk factors.

"Given that up to one-third of Australians have non-alcoholic fatty liver disease, and the subsequent rate of progression to NASH is around 30 per cent, the impact on the community is significant."

Study participants will complete 12 weeks of HIIT supervised by an accredited exercise physiologist at UQ's St Lucia campus in Brisbane, followed by 12 weeks of HIIT at home.

"The sessions will involve short, intense bursts of exercise around four minutes on a treadmill or exercise bike at near maximum capacity - interspersed with more moderate exercise," Dr Keating said.

"Health measures including insulin sensitivity, body composition, vascular function, and fitness will be assessed before and after the supervised and home-based phases.

"It is very important that individuals can continue on with HIIT in the long-term so that the health benefits can be sustained," Dr Keating said.

People with biopsy-proven NASH, or their clinicians, should contact Dr Keating (see below) for details on how to take part in the trial.

Explore further: Diet and exercise can improve kidney function in patients with fatty liver disease

Non-alcoholic steatohepatitis (NASH) is a potentially serious liver condition characterized by excess fat in the liver associated with inflammation and scarring. NASH may progress to cirrhosis of the liver and liver cancer, ...

(Medical Xpress)High-intensity interval training (HIIT) is touted as the fastest way to get lean, but according to ground-breaking new research from the University of Sydney's Charles Perkins Centre, only endurance exercise ...

A University of Queensland researcher is trialling a 12-minute exercise plan that aims to fight type 2 diabetes in a flash.

Listening to music may make it easier for people to adopt short duration exercise regimens that could help them stay in shape, according to researchers at UBC's Okanagan campus.

Understanding how exercise affects language learning could help patients with brain conditions such as stroke, Alzheimer's and Parkinson's disease.

Time-poor people who do fewer repetitions during high-intensity interval training (HIIT) workouts may get better fitness benefits than those who complete more, according to a University of Stirling analysis.

Short bursts of high-intensity exercise could help people with non-alcoholic fatty liver disease reduce their risk of type 2 diabetes.

A diet designed to imitate the effects of fasting appears to reverse diabetes by reprogramming cells, a new USC-led study shows.

(Medical Xpress)A team of researchers with members from several institutions in Germany and one in the U.K. has discovered what might be a way to tell if a newborn child is likely to develop type 1 diabetes as they grow ...

People with diabetes are at high risk of developing heart disease. Despite knowing this, scientists have struggled to trace the specific biology behind that risk or find ways to intervene. Now, UNC School of Medicine researchers ...

A long-term study by Monash University researchers - the first of its kind - has found that gastric band surgery has significant benefits for moderately overweight people with type 2 diabetes. Previous studies have focused ...

Blood sugar triggers the secretion of insulin from cells in the pancreas, a process that is impaired in diabetes. A team of Yale researchers have identified a mechanism at the membranes of these pancreatic cells that controls ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

More:
Can fast and furious exercise prevent diabetes? - Medical Xpress

Ever since he was diagnosed with Type 1 diabetes as a fifth-grader at Claremont Elementary School, Alex Simmons has been committed to raising funds for the Juvenile Diabetes Research Foundation (JDRF).

Now a Washington-Lee High School sophomore, he moves closer to his goal of raising $100,000 for diabetes research during a Feb. 25 event that drew more than 130 neighbors and friends to the Lyon Park Community Center.

The party, which included a silent auction, was hosted by five Arlington families who have supported Simmons since his diagnosis. The event raised more than $15,000, with all proceeds going directly to the JDRF, and boosted Alex Simmonss fund-raising totals so far to $75,500 in donations.

Ever since our son Alex was diagnosed with diabetes five years ago, the JDRF has been a big part of our lives, said Anita Simmons, a new member of the board of directors of the Juvenile Diabetes Research Foundation Greater Chesapeake and Potomac Chapter. They provide hope and guidance for so many families as we learn to cope with this diagnosis and protect our childrens health.

At the celebration, guests enjoyed a fully catered dinner by the Hard Times Caf, beverages from Dogfish Alehouse, a silent auction and the musical sounds of the Roger Taylor Quartet as they connected over a common cause.

Many Arlington businesses made donations, including local artist Sabrina Cabada, independent bookstore One More Page and SPARK Business Academy.

Previous fund-raisers have included local basketball tournaments, small parties with a purpose and a bingo night hosted by Simmons grandmother, Alease Brooks, a resident of Arlingtons The Carlin.

Bill Parsons, executive director of the Greater Chesapeake and Potomac Chapter, said the Feb. 25 event was one of the largest peer-to-peer fund-raising events his organization has seen in this area.

The commitment this family has made to bringing awareness to juvenile-diabetes issues and raising money for research has been incredible, he added. We all love the Simmons family Anita Simmons is a force of nature.

Complications of juvenile diabetes can be disabling and life-threatening. Each day, Alex Simmons who over the winter played on the varsity boys basketball team at Washington-Lee must monitor his blood sugar levels and give himself six to eight insulin shots, yet he remains focused on the positive.

I am not on this journey alone, and my close friends, family and relatives make this process much easier for me, he said. I encourage everyone who can to please donate money to the Juvenile Diabetes Research Foundation, not only for me, but for all of the children throughout the country who dont have it as easy as I do.

Alex Simmons is now a youth ambassador for the organization, and also leads a team that takes part in the annual OneWalk event on the National Mall.

Anita Simmons said their family is especially grateful to Rich Kelly and Cindy MacIntyre of the Hard Times Caf for providing all of the food for the fund-raising event, as well as for the help they extended to Alex and his family when he was first diagnosed with the disease. The Kellys daughter also has Type 1 diabetes, and they are strong supporters of Juvenile Diabetes Research Foundation.

For information on Alex Simmons fund-raising efforts, see the Web site at http://bit.ly/2mmGi5g.

Read the original:
Washington-Lee student working to raise $100000 for diabetes research - Inside NoVA

When the Kansas Senate comes back after this weeks midsession break, it may consider legislation to form a comprehensive state plan to fight diabetes.

House Bill 2219 would instruct the Kansas Department of Health and Environment to conduct an analysis of state costs from diabetes, identify best practices to prevent and control the condition, and develop a budget to implement those practices.

It also would require the agency to report on the plans progress every two years.

Just before the break the House voted 117-7 to pass the bill, which is one of the main legislative priorities for the American Diabetes Association. Four other states passed similar plans in 2016, according to the organization.

According to the American Diabetes Association, diabetes affects almost 13 percent of the adult population in Kansas and leads to about $2 billion in health care costs annually.

The associations numbers include an estimated 69,000 Kansans who have undiagnosed diabetes. Numbers from the federal Centers for Disease Control and Prevention that include only those with diagnosed diabetes ranked Kansas at 21st highest in the country, at 9.5 percent.

People with diabetes are unable to produce or properly use insulin, a hormone that turns food into energy. There are two main forms:Type 1 diabetes, previously known as juvenile diabetes, andType 2 diabetes, the most common kind. Common complications of diabetes include heart and blood vessel disease, kidney damage, blindness and nerve damage.

Larry Smith is president of the National Diabetes Volunteer Leadership Council, a Kentucky-based nonprofit that testified for the Kansas bill. He said Kentucky was the first state to enact a diabetes action plan and about one-third of states have them now.

It has opened the eyes of the Legislature and the government that there is a problem and its a big drain on their budget, said Smith, whose daughter has Type 1 diabetes.

Smith said the push to fight diabetes in Kentucky began with Gov. Ernie Fletcher, a Republican physician who led the state from 2003 to 2007.

He realized the cost that diabetes put on the state budget was substantial and held them back on a number of things they wanted to do in terms of education or infrastructure and so forth, Smith said.

A similar bill died in the Kansas House in 2015. But Rep. Susan Concannon, a Republican from Beloit who brought this years bill, said the current version was voted through in part due to testimony from Rep. Blaine Finch, a Republican from Ottawa, and from his teenage daughter who has diabetes.

It was a little more meaningful for us this year to have one of our colleagues make it more personal, Concannon said.

Andy Marso is a reporter for KCURs Kansas News Service, a collaboration of KCUR, Kansas Public Radio and KMUW covering health, education and politics in Kansas. You can reach him on Twitter@andymarso. Kansas News Service stories and photos may be republished at no cost with proper attribution and a link back to kcur.org.

See more here:
Anti-Diabetes Plan Progressing In Kansas Legislature | KCUR - KCUR

February 28, 2017 4:21 PM

Wounds that wont heal can become a major health risk for diabetics and protecting yourself is the best prevention according to Dr. Nathaniel Holzman, Medical Director of the St. Mary Wound Healing Center in Langhorne. He says patients can help themselves by keeping their diabetes in good control, eating a healthy diet, exercising regularly, and maintaining healthy skin. He says cracks in the skin can allow bacteria to enter which may lead to infection. He also urges people to regularly see a podiatrist for preventative foot care to manage risk factors before wounds occur.

If a patient does present with a wound that has been an issue for a while, there are different treatments available. First, Dr. Holzman makes certain there is sufficient blood flow to the region, as blood flow is essential in wound healing. Also, swelling must be controlled and is initially managed with compression. Establishing healthy eating patterns for good sugar control is also very important. Some times, wounds present with infection that may require antibiotics. At times, surgery may also be necessary. Dr. Holzman says hyperbaric oxygen therapy may also be needed to aid in the healing process.

Unfortunately, diabetes is on the rise as people gain weight and adopt more sedentary lifestyles. As diabetes is a chronic condition, patients need to do everything possible to keep it under control and maintain good health. He urges people to eat nutritious food, maintain a healthy weight, keep active, and adopt a good skin care regimen.

Sponsored Content Provided by St. Mary Medical Center

5 Phillies Players To Watch This Spring Training

Best Places To See Indie Rock In Philly

Read the original post:
Non-Healing Wounds Related to Diabetes - CBS Philly

International Stem Cell Corporation Announces Third Patient with Parkinson's Disease in Phase I Clinical Trial P&T Community 28, 2017 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced the third patient in the clinical trial ... and more »

Read the rest here:
International Stem Cell Corporation Announces Third Patient with Parkinson's Disease in Phase I Clinical Trial - P&T Community

Trials at UNC yield 'rebirth' for 2-time cancer survivor WRAL.com Shea, a UNC Lineberger member and medical director at the UNC Bone Marrow and Stem Cell Transplant Program, suggested that Dale participate in the trial in which researchers remove a patient's immune cells, called T cells, then genetically engineer ... and more »

View post:
Trials at UNC yield 'rebirth' for 2-time cancer survivor - WRAL.com

World-first genetic clues point to risk of blindness -- ScienceDaily Science Daily Scientists have discovered the first evidence of genes that cause Macular Telangiectasia type 2 (MacTel), a degenerative eye disease which leads to blindness ... and more »

Read more:
World-first genetic clues point to risk of blindness -- ScienceDaily - Science Daily

Diabetics who may be experiencing vision loss without realizing it are the target of a new awareness campaign St. Josephs Health Care London hopes will lead to more screening.

Vision loss can be sneaky, said London-based optometrist, Harry Van Ymeren, in a news release. In my practice, I have seen it many times. People think they are fine and we discover a problem. The point of screening is to catch it before it becomes too late.

Diabetes is a chronic disease that prevents the body form making or using insulin, in turn increasing sugar levels in the blood stream. The development of early-onset cataracts and glaucoma is more likely for people who have diabetes, but Tom Sheidow, an ophthalmologist at the Ivey Eye Institute, said the main threat is the effect of diabetes on the retina, the part of the eye that allows you to see.

This is why screening early and often is so important for those with diabetes, he said. Diabetes can affect all blood vessels in your body, including those inside your eye. Diabetic eye damage, also called diabetic retinopathy, occurs when there is a weakening of the blood vessels in the retina that can result in swelling, the abnormal growth of blood vessels, and potentially severe bleeding. If diabetic retinopathy is left untreated, blindness can result.

According to St. Joes, estimates put the number of people in Canada with some form of diabetic retinopathy at around two million. It is the most common cause of blindness in people under age 65 and the most common cause of new blindness in North America.

Sarah MacArthur was diagnosed with type 1 diabetes at the age of three and has been cautious with her care because she understands the importance of screening. MacArthur said she has discovered symptoms of diabetic retinopathy in the past four years because of screenings with Van Ymeren.

I had no signs at all, she said. There was nothing that prompted me or made me think something was wrong with my vision. We are keeping a close eye on any changes so we know immediately if there is a concern.

A routine eye examination is all it takes to diagnose potentially threatening changes that can cause blindness. But once damage has occurred, the effects can be permanent.

People who feel completely healthy are the focus of this diabetes vision screening awareness campaign, said Sheidow. Anyone with diabetes (both type 1 and type 2) should have their vision checked.

Referrals to an optometrist from a family doctor are not required and in Ontario, the cost of an eye exam for people living with diabetes is covered through OHIP. Resources to locate an optometrist are available at opto.ca. For communities without an optometrist, an ophthalmologist is an option, said Van Ymeren.

It doesnt matter if you see an ophthalmologist or an optometrist, as long as you get your eyes checked. Yearly screening is free for people with diabetes.

For more information, visit diabetesvisionscreening.ca

Read more:
Did you know diabetes can cause blindness? - Londoner

DETROIT Scientists with Wayne State University say they are the first to publish research to show the Zika virus can damage retina cells in the eyes, and in some cases cause blindness.

The key message of the study is that indeed the Zika virus can cause damage, said Dr. Ashok Kumar, microbiologist and assistant ophthalmology professor with Wayne State University School of Medicine at the Kresge Eye Institute.

Dr. Kumar led a team which launched research in July to publish their study in JCI Insight, the Journal of Clinical Investigation Feb. 23.

Using mice Dr. Kumar says the Zika virus can infect and cause lesions in retina cells, causing damage and in some cases cause blindness. Their research showed the Zika virus mostly killed cells specifically lining the blood-retinal barrier, the retinal endothelium, and retinal pigment epithelium.

Zika virus can actually infect those cells, and we did studies and we found it can replicate in those cell types and ultimately it kills those cells, said Dr. Kumar.

Their study builds on existing research published May 2016 in the Journal of the American Medical Association Ophthalmology that linked the Zika virus to eye problems. Researchers showed that some infants born with congenital Zika infection and microcephaly-or significantly smaller head and underdeveloped brain-in the northeast state of Brazil, Bahia, they also had problems in their retinas, other organs, and some hearing loss.

Pretty much the whole eye can be infected with the Zika virus, said Dr. Gary Abrams, ophthalmology professor with Wayne State University School of Medicine at the Kresge Eye Institute, who assisted Dr. Kumar with the clinical aspect of this study.

Dr. Abrams says about one third of infants born with Zika will develop eye issues they have discovered, whereas 15 percent of adults with Zika will have some sort of ocular impact, but most do not get a retinal infection.

This is a virus thats fairly pervasive: once the infection occurs it can be pretty much all over the body, including in the eyes, in the tears, and elsewhere, said Dr. Abrams.

Currently, Dr. Kumar says they are continuing research in hopes of developing methods to track and treat Zika infections. According to the Centers for Disease Control and Prevention, there is no known treatment at this time.

There are so many questions we dont know, said Dr. Kumar. First thing is: how does the virus replicate? How long is it going to replicate? And what will be the visual outcome.

The big question really is that Zika virus was discovered in 1947, so its about 70 years, and why suddenly is it becoming so prevalent?

View original post here:
Wayne State University scientists discover the Zika virus can ... - Fox17 - Fox17

Posted Feb. 28, 2017 at 3:39 p.m.

Published: 2017-02-28 15:39:55 Updated: 2017-02-28 15:39:55

By JIM SHAMP, NCBiotech Writer

Raleigh, N.C. The North Carolina Biotechnology Center has announced that Pfizer has committed to providing funding in the amount of $4 million which will enable the Center to establish and administer a multi-year academic fellowship program to help advance North Carolinas fast-growing expertise in gene therapy.

The new program, to be managed by NCBiotech, will support distinguished postdoctoral fellowships in North Carolina university research laboratories providing advanced scientific training in gene therapy-related research.

Absent or faulty proteins linked to genetic mutations cause numerous devastating diseases, making gene therapy an increasingly important treatment strategy.

Pfizers portfolio in North Carolina has grown in recent years. The company already operates a pharmaceutical manufacturing facility in the Lee County community of Sanford, and in August 2016, it acquired leading-edge gene therapy company Bamboo Therapeutics, Inc. in Chapel Hill.

With that acquisition, Pfizer gained the expertise of Bamboos world-renowned co-founder, R. Jude Samulski, Ph.D., director of the Gene Therapy Centerat the University of North Carolina at Chapel Hill. The deal also included an 11,000-square-foot facility for the highly specialized manufacturing of recombinant adeno-associated viral vectors.

Pfizer is one of several biopharmaceutical companies that have added high-profile gene therapy acquisitions, and several partnerships with biotechnology companies and leading academic institutions, to its R&D portfolio. Numerous other North Carolina scientists and companies are also making significant inroads into gene therapy, gene editing and related applications, many with NCBiotech support. For example, Samulski was recruited to UNC in 1993 as part of a $430,000 NCBiotech grant. Additionally, Bamboos former parent company received more than $700,000 in Biotech Center grants and loans.

Gene therapy advances require specific skills in addition to deep scientific knowledge. The fellowship program being established with Pfizers funding aims to boost that talent pipeline, with talent that has already proven to be exceptional in North Carolina. Such funding will enable NCBiotech to provide two-year fellowship support to postdoctoral scientists. The funding will afford the Center the ability to cover salaries, benefits, materials, professional development and travel for such postdoctoral scientists. The Center will encourage competitive applications from scientists interested in establishing research careers in gene therapy and related research activities.

The Biotech Center will also create and manage a related gene therapy Exchange Group. It will join some 25 other exchange groups designed to unite North Carolina-based academic and industry scientists with shared professional interests. The Gene Therapy EG will include these new postdoctoral fellows, their mentors, and others interested in the burgeoning gene therapy sector.

The field of gene therapy research has made tremendous strides in recent years, and we are pleased to be able to further enhance our leadership position in this area through this unique fellowship program, said Mikael Dolsten, M.D., Ph.D., president of worldwide research and development at Pfizer. We believe that gene therapy may hold the promise of bringing true disease modification for patients suffering from devastating diseases, and North Carolina is uniquely positioned to help us take advantage of collaborative opportunities that can develop the specialized talent well need.

Doug Edgeton, president and CEO of the Biotech Center, said he was deeply honored that Pfizer targeted North Carolina, and the Center, for the groundbreaking fellowship program.

Pfizer embraced the opportunity to work with us given weve proven for more than 30 years that we have the expertise and success metrics to maximize impact, said Edgeton. We not only have outstanding research institutions across our state, but we also have a well-respected culture of partnering and collaboration that allows us to be nimble and responsive. This is a wonderful example.

(C) N.C. Biotechnology Center

WRAL TechWire any time: Twitter, Facebook

Excerpt from:
Pfizer commits $4M to NC Biotechnology Center gene therapy ... - WRAL Tech Wire

Jordan High School senior Jack Friedges will serve as the 2017 Walk to Cure Juvenile Arthritis Young Adult Honoree this weekend at the Mall of America.

Walk to Cure Juvenile Arthritis brings together communities nationwide to fight arthritis the nations leading cause of disability.

In the U.S., more than 50 million adults and 300,000 children live with arthritis. Costing the U.S. economy $156 billion dollars a year, arthritis affects one in five Americans and causes more activity limitation than heart disease, cancer or diabetes.

Friedges, age 17, was diagnosed with juvenile idiopathic arthritis (JIA) in 2014. His parents believe he had signs of JIA throughout his childhood but attributed them to other causes. Friedges was very active; he was and continues to be a three-sport athlete playing football, basketball and his favorite sport, baseball.

At age 13, Friedges started complaining about odd sensations in his hands and that his fingers were big, fat and did not work. Friedges and his parents thought his sore hands were related to his active life.

Eventually, Friedges mom started noticing more and more that he was not using his hands. His brother would change the fishing line for him, he had trouble tying his shoes or buttoning his shirts and she saw how much Friedges was relying on his brother to do these tasks for him. Over several months, Friedges was officially diagnosed with JIA and his pain started to intensify and spread to his hands, feet, knees, elbows, shoulders and back.

Although Friedges optimistic attitude was unbeatable, it was a difficult time for their family. After six months of pain, Friedges medication started working and his pain and swelling decreased dramatically. Friedges has taken charge of his health, learning about his medication side effects and what triggers swelling or pain.

He does all this while being the most positive member of our family when it comes to this diagnosis, says Friedges mom. His strength to move on, stay positive and be in control of his life is astonishing.

Friedges, as the Young Adult Honoree, and his family want to help raise money for a cure as well as spread awareness about JIA. They may be uncertain of Friedges future but appreciate the resources, education and hope that the Arthritis Foundation has provided them. They are positive that JIA will not define Friedges future and he will be the champion of his own life.

See more here:
Jack Friedges named Arthritis Foundation 2017 Young Adult Honoree - SW News Media

Clinical Pain Advisor (registration)

Marine Oil Supplementation for Rheumatoid Arthritis Clinical Pain Advisor (registration) Because rheumatoid arthritis (RA) is characterized by chronic inflammation, it is not surprising that researchers have long been interested in whether omega-3 supplements can improve RA symptoms. In a review article, Dr Tedeschi and associate Karen ...

Excerpt from:
Marine Oil Supplementation for Rheumatoid Arthritis - Clinical Pain Advisor (registration)

NEW YORK, Feb. 28, 2017 /PRNewswire/ -- The global medical marijuana market is expected to reach a value of USD 55.8 billion by 2025, according to a new report by Grand View Research, Inc. It has been identified that, in 2016, Washington D.C. along with 28 states have legalized marijuana for medical uses. In 2016, states such as Arkansas, Florida, North Dakota, Ohio, and Pennsylvania were approved to use the drug in medical applications such as chemotherapies and pain management. The growing number of states and countries getting approval for using it in therapeutic applications is one of the crucial factors driving the demand over the coming few years.

The presence of several regulatory frameworks such as the Medical Marijuana Regulation and Safety Act is indicators of the present demand for the drug in the market. The regulatory framework requires every individual or the company associated such as growers, retail operators, and makers of processed pot products to obtain permission and an annual state license from 2018. An increasing number of issued licenses is also among factors that is expected to drive the market especially after 2018.

The increasing interest amongst the academic researchers and healthcare providers regarding the therapeutic uses of marijuana is among the significant factors, which is driving the market over the coming years. Some of its potential therapeutic values are suppression of vomiting & nausea, pain relief, and appetite stimulation. In addition, research states that marijuana is effective in providing relief to the patient suffering from HIV/AIDS, glaucoma, cancer, and multiple sclerosis. The growing number of therapeutic applications of the drug is one of the key factors that is propelling the market over the forecast period.

Further key findings from the study suggest:

In 2015, chronic pain was the largest application segment owing to the presence of a huge patient base

The growing prevalence of chronic pain elevates the demand for the drug, thus expected to boost the medical marijuana for chronic pain management

The rapidly growing number of cannabis legalization in the U.S. is one of the key attributes for its increased demand in therapeutic and recreational uses, and thus anticipated to impel the market growth

Increasing investment in R&D & demand for cannabis in chemotherapy is expected to drive the growth in the Asia Pacific market

Some of the key players are Cara Therapeutics Inc.; CannaGrow Holdings, Inc.; Cannabis Sativa, Inc.; United Cannabis Corporation; GrowBlox Sciences, Inc.; GW Pharmaceuticals, plc; Lexaria Corp; International Consolidated Companies, Inc. Read the full report: http://www.reportlinker.com/p04717523-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medical-marijuana-market-analysis-by-application-chronic-pain-arthritis-migraine-cancer-by-country-us-canada-france-italy-switzerland-israel-belgium-croatia-finland-netherlands-portugal-czech-republic-estonia-300415515.html

Originally posted here:
Medical Marijuana Market Analysis By Application, (Chronic Pain, Arthritis, Migraine, Cancer) By Country (US, Canada ... - Yahoo Finance

She credits an experimental stem cell treatment with giving her new hope for her health and her future -- a newfound hope that also caught attention of Republican Rep. Pete Olson.

"She is the face of the 21st Century Cures Act because of what she's gone through in her life," he said Tuesday.

"It became pretty clear to me that ... I (have) got to tell her story," he said. "That's why she's here: She's awesome."

Immediately after the House vote, Hughes said, Olson called her at home to invite her to be his guest of honor.

"I still cannot believe I will be in the same room as our President and lawmakers," she said before attending Trump's speech.

It took Crowley's father, John, to launch the New Jersey biotechnology company Amicus Therapeutics to identify a drug treatment that would save her life, Trump said.

"If we slash the restraints, not just at the FDA but across our Government, then we will be blessed with far more miracles like Megan," he said. "In fact, our children will grow up in a Nation of miracles."

Hughes spent most of her adolescence hospitalized, as she became so sick that she could barely walk and suffered immense pain. Her body was evaluated, treated and studied at the National Institutes of Health in collaboration with her doctors from the University of Texas Health Science Center at Houston.

Yet relief came in 2014, when Hughes received a high-dose adult stem cell treatment that was not approved in the United States.

For the procedure, Hughes had her own healthy stem cells cultured at the FDA-registered biotechnology company Celltex Therapeutics in Houston. Then she traveled to Cancun, Mexico, to have the cells infused back into her body.

Each infusion involved about 200 million stem cells, and Hughes received some 22 infusions over almost two years. The cells could help normalize her immune system, which was overactive due to her autoimmune disease.

Before the stem cell therapy, Hughes said, she was taking 23 medications a day. Now, she is on eight medications at lower doses.

"If not for the help of high-dose autologous mesenchymal stem cell therapy, I would not be here today," Hughes said at the hearing.

"I was running out of time, but I was willing to put my life at risk to get on an airplane. My quality of life had become so dismal, even one small improvement from my own stem cells would have been enough for me," she said in her speech. "What happened in the days, weeks and years following my first infusion has changed my outlook. It's hard to believe, in my sick body, I had a wealth of healthy adult stem cells with the ability to so significantly improve my quality of life."

"My hope is that our new President will spend time looking at how to help all Americans have access to new therapies like the one I had," she said.

Go here to read the rest:
Stem cell treatment changed the life of one guest at Trump's speech - CNN

PUNE, India, February 28, 2017 /PRNewswire/ --

According to a new market research report "Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Surgery, and aGVHD), Cell Source (Adipose tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs) - Global Forecasts to 2021" published by MarketsandMarkets, the market is expected to reach USD 145.8 Million by 2021, growing at a CAGR of 11.0%.

(Logo: http://photos.prnewswire.com/prnh/20160303/792302 )

Browse 60 market data Tables and 37 Figures spread through 120 Pages and in-depth TOC on "Stem Cell Therapy Market"

http://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html

Early buyers will receive 10% customization on this report.

The report analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the world (RoW) for the forecast period of 2016 to 2021. Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global Stem Cell Therapy Market.

On the basis of type, the global Stem Cell Therapy Market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy. The allogeneic stem cell therapy segment is expected to command the largest share in the global Stem Cell Therapy Market in 2016. This large share can primarily be attributed to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, and growing number of clinical trials related to allogeneic stem cell therapies.

Inquiry Details: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=48

On the basis of therapeutic application, the global Stem Cell Therapy Market is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications. The musculoskeletal disorders segment is expected to command the largest share of the global Stem Cell Therapy Market in 2016. This large share can be attributed to the rising availability of stem cell-based products for the treatment of musculoskeletal disorders, high prevalence of musculoskeletal disorders and bone & joint diseases, and growing patient preference for effective & early treatment strategies.

North America is expected to be the largest regional segment in the global Stem Cell Therapy Market in 2016, followed by Asia-Pacific. In addition, the North American Stem Cell Therapy Market is expected to be the fastest growing region during the forecast period. Factors such as growing awareness related to the therapeutic potency of stem cells, increasing number of clinical trials for stem cell-based products, and increasing public-private funding & research grants are driving the growth of this market.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=48

As of 2015, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) are some of the key players operating in the global Stem Cell Therapy Market.

Browse Related Reports:

Stem Cell Assay Market by Type (Viability, Differentiation, Cell Identification), Kit (Mesenchymal, IPSCS, Hematopoietic), Product (Flow Cytometer, Detection Kit), Application (Regenerative Medicines, Drug Development), End User - Forecast to 2021

http://www.marketsandmarkets.com/Market-Reports/stem-cell-assay-market-47610330.html

Stem Cell Banking Market by Bank Type (Cord Blood, and Cord Tissue), Service (Collection & Transportation, Analysis, Processing, and Storage), Application (Cerebral Palsy, Leukemia, Thalassemia, Anemia, Autism, Diabetes), Region - Forecast to 2021

Read More

http://www.marketsandmarkets.com/Market-Reports/stem-cell-banking-market-220680183.html

About MarketsandMarkets:

MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to a multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact: Mr. Rohan MarketsandMarkets 701 Pike Street Suite 2175, Seattle, WA 98101, United States 1-888-600-6441 Email: sales@marketsandmarkets.com

Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology

Connect with us on LinkedIn @http://www.linkedin.com/company/marketsandmarkets

Original post:
Stem Cell Therapy Market Worth 145.8 Million USD by 2021 - Yahoo Finance

KARAIKAL: Recent advancements in stem cells research have given hope for successfully treating diabetic heart disease (DHD), renowned New Zealand-based researcher in cardiovascular diseases Dr Rajesh Katare said today.

DHD affected the muscular tissues of the heart leading to complications and it had been demonstrated that resident stem cells of myocardium can be stimulated to repair and replace e degenerated cardiac myocytes resulting in a novel therapeutic effect and ultimately cardiac regeneration, he said.

Katare, Director of Cardiovascular Research Division in the University of Otago, New Zealand, was delivering the keynote address at the continuing medical education programme on "Role of Micro-RNAs and stem cells in cardiac regeneration in diabetic heart disease" at the Karaikal campus of premier health institute JIPMER.

Presenting clinical evidences, Katare said stem cell therapy certainly presented a new hope for successfully treating DHD.

Jawaharlal Institute of Post Graduate Medical Education (JIPMER) Director Dr Subash Chandra Parija pointed out that it was the first such programme on the role of stem cells in cardiac regeneration in the whole of the country.

He said as diabetes was highly prevalent in the country, providing treatment for DHD had become a big challenge. Patients suffering from the condition have to undergo lifelong treatment and medications. "In this backdrop, advancements in stem cell therapy assume significance," he said.

See the original post here:
Stem cell therapy can help treat diabetic heart disease - The ... - Economic Times

AstraZeneca (AZN) stock gained in early London tradingTuesday after it received approval from the U.S. Food and Drug Administration for a type-2 diabetes medication.

The London-listed drugmaker said it had received approval for Qtern, a once-daily treatment for type-2 diabetes, which affects more than 29 million American. The approval comes after the company's breast cancer treatment, Lynparza, was shown to be more effective than chemotherapy.

AstraZeneca shares were marked 1.07% higher at 4,658 pence each by 08:45 GMT, extending a 9.46% gain in the past three months, largely in-line with the 8.9% advance for the Stoxx Europe TMI Pharmaceuticals Index.

"Type-2 diabetes is a complex disease that is at epidemic proportions ... The approval of Qtern is good news for patients who may benefit from improved glycaemic control by adding a DPP-4 inhibitor to a SGLT-2 inhibitor in a convenient once-daily tablet," said AstraZeneca's vice president and head of cardiovascular and metabolic diseases Elisabeth Bjork.

Qtern combines two anti-hyperglycaemic agents with complementary mechanisms of action in a once-daily tablet: Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor; and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor.

Diabetes is a core therapy area for the company, focusing on research and development efforts on diverse populations and patients with other disease such as cardiovascular disease, obesity, non-alcoholic steatohepatitis and chronic kidney disease.

The company earlier this month said that a new oncology treatment Lynparza has shown to be more effective than chemotherapy in treating metastic breast cancer.

Original post:
AstraZeneca Shares Rise After FDA Approval for Type-2 Diabetes Treatment - TheStreet.com

New research shows that a diet which mimics fasting might be able to push beta cells in the pancreas to repair themselves and start making insulin again.

BBC news reported that for the research study, mice in the lab were put on a modified form of the fasting-mimicking diet. The diet is similar to the human practice of spending five days on a low-calorie, low-protein, low-carbohydrate diet. It resembles a vegan diet with nuts and soups, but with around 800 to 1,100 calories a day. Then they have 25 days eating what they want so overall it mimics periods of feast and famine, says BBC news.

A press release on Eureka Alert explained that the researchers used two different mouse models of two types of diabetes to study how the diet affected the mice. One group had a gene mutation that causes insulin resistance and loss of insulin secretion, which mimicked type 2 diabetes. The other group was treated with a chemical to destroy the mices beta cells, which was the model for type 1 diabetes. Both groups were put on the diet for three cycles.

Excitingly, this diet showed the possibility of regeneration of insulin-producing cells in the pancreas which had stopped or slowed production of insulin in people with type 1 and type 2 diabetes, respectively.

Senior author of the study, Dr. Valter Longo of the University of Southern California School of Gerontology and Director of the USC Longevity Institute, told Eureka Alert, Our conclusion is that by pushing the mice into an extreme state and then bringing them backby starving them and then feeding them againthe cells in the pancreas are triggered to use some kind of developmental reprogramming that rebuilds the part of the organ thats no longer functioning.

Studies suggest the diet could be a way to reboot the body by inducing it to slow down aging and regenerating new cells, reports Eureka Alert.

Dr. Longo told BBC: Medically, these findings have the potential to be very important because weve shown at least in mouse models that you can use diet to reverse the symptoms of diabetes. Scientifically, the findings are perhaps even more important because weve shown that you can use diet to reprogramme cells without having to make any genetic alterations.

The intermittent fasting diet has been trialed on humans for various purposes, and it has shown improved blood sugar levels. However, people are advised not to try this diet on their own because it could have a detrimental impact on their health if not done with proper medical guidance.

A BBC reporter, Peter Bowes, took part in a separate trialwith Dr. Valter Longo several years ago .

Bowes told BBC: During each five-day fasting cycle, when I ate about a quarter of the average persons diet, I lost between 2kg and 4kg (4.4-8.8lbs).

But before the next cycle came round, 25 days of eating normally had returned me almost to my original weight. But not all consequences of the diet faded so quickly.

According to the BBC, his blood pressure was lower as was a hormone called IGF-1, which is linked to some cancers.

On February 15, Longos team published a Phase II study that was carried out in 100 humans who were exposed to three rounds of the same diet. According to Eureka Alert, their IGF1 levels decreased and their fasting glucose levels improved, among other findings.

However, the team says more research is needed before the findings can be validated for application in humans. Longo told Eureka Alert that future clinical trials are already being planned.

The research findings were originally published in the journal Cell.

Elizabeth Rowley is the Founder and Director of T1International. She was born in the United States and has lived with type 1 diabetes for 25 years. Elizabeth moved to London in 2011 to complete her Masters degree in International Development at the London School of Economics and Political Science and has worked with non-profits, diabetes and health organizations ever since. She believes that where you were born should not determine whether you live or die with diabetes, and she is confident that by working together we can find solutions to the complex problems faced by people with diabetes.

Read more here:
Fasting Diet for People With Diabetes Could Regenerate the Pancreas - A Sweet Life

People with diabetes have to think about their condition and make treatment decisions constantly and all that extra work and worry can lead to psychological distress at times.

"Diabetes distress" isn't the same as depression, diabetes experts note. It's a condition unique to the 24/7 demands that come with diabetes, particularly for people dependent on insulin.

"The day you develop diabetes, it's like the universe just handed you a new full-time job that you have to do in addition to whatever else you're doing. It's a special job that has a big impact on the rest of your life. There's no pay and no vacation," said William Polonsky, president of the Behavioral Diabetes Institute in San Diego.

RELATED: TRENDING LIFE & STYLE NEWS THIS HOUR

Alicia McAuliffe-Fogarty, vice president of lifestyle management at the American Diabetes Association, put it this way: "Diabetes distress is the extra burden that people with diabetes have to carry. They have to do everything that other people do take care of work, family, finances and in addition they have to make sure to check their blood sugar, remember to take their medicine and/or adjust their insulin doses, count carbohydrates when they eat.

"It's a day-to-day and minute-to-minute burden. It's doing everything 'right' and still seeing your blood sugar levels go up," she added.

Diabetes distress is a range of different emotional responses that come with dealing with the burdens of caring for diabetes, Polonsky explained.

"It's being fed up and overwhelmed with the demands and concerns of diabetes. It's feeling powerless in the face of diabetes. It's knowing that despite your best actions, sometimes those [insulin] numbers go up and down and it seems beyond your ability to influence. And it can negatively influence one's quality of life," he added.

The phenomenon hasn't been well-studied Polonsky said he and his colleagues are in the middle of a study on diabetes distress that will hopefully answer some questions about the condition that affects an estimated 30 percent of people with diabetes at some point in their lives.

"It's not everybody, and it's not all the time, but it's pretty darn common, and a whole lot more common than depression" among those with diabetes, Polonsky added.

Diabetes distress and other psychological conditions are common enough that the American Diabetes Association added a section to its guidelines, published recently in the journal Diabetes Care, suggesting that providers screen all of their diabetes patients for these mental health concerns.

Juggling job with no breaks

There are two main types of diabetes: Type 1 and Type 2.

People with Type 1 diabetes don't make enough insulin, a hormone the body needs to use the carbohydrates in food for fuel. Because of this, people with Type 1 rely on insulin injections or insulin delivered through a tiny catheter inserted under the skin and then attached to an insulin pump worn outside the body. People with Type 1 diabetes using shots may need five or six insulin injections daily.

In people with Type 2 diabetes, the body is no longer able to use insulin properly. Most (95 percent) of diabetes cases involve the Type 2 form. Sometimes, people with Type 2 diabetes also need to use insulin injections.

Using insulin is a difficult balancing act too much or too little can cause problems, even life-threatening ones. When blood sugar levels drop too low from too much insulin, people can become disoriented, and if levels drop even further, they may pass out. Blood sugar levels that are too high and left untreated over time can cause complications such as kidney troubles, eye problems and heart disease.

To keep track of blood sugar levels when using insulin, most people rely on glucose meters and a lancing device that pricks the finger to draw out a drop of blood. This may be done as few as 4 times a day, or as many as a dozen or more times daily, depending on how blood sugar levels are fluctuating.

Many factors besides insulin can influence blood sugar levels. Food, alcohol, physical activity, emotions such as stress, and illness all can cause unpredictable changes in blood sugar levels.

Strength in numbers

Both Polonsky and McAuliffe-Fogarty said it's important to recognize and treat diabetes distress because it can have a negative impact on blood sugar management.

"In some studies, diabetes distress can impact diabetes care more than depression," McAuliffe-Fogarty said.

Antidepressants aren't likely to help someone with diabetes distress, according to Polonsky.

McAuliffe-Fogarty suggests checking in with your health care provider so you can go over your current diabetes management regimen. It's possible that changes in your management might help, she said.

Or, it might help to have a visit with a diabetes educator to go over some of the basics again, she recommended. Many people with Type 1 diabetes are diagnosed as children, and as adults may not realize they're missing some of the basics of diabetes education.

"Maybe pick one or two things that would make the most impact on your management and focus on those one or two small things, and you'll likely achieve those goals. Then set one or two more goals and move along like that not everything needs to happen at once," McAuliffe-Fogarty said.

Both experts agreed that support is an important component of treating diabetes distress. "You don't want to do diabetes alone. If you have someone who's rooting for you, that really helps," Polonsky said.

He said parents or spouses can give a person with diabetes a break by taking over the management of the disease for a little while. It gives them a "diabetes vacation."

For some, distress can get more serious. McAuliffe-Fogarty said about one in every four or five people with diabetes will experience depression at some point.

She said signs that suggest you need to speak with a mental health professional include: changes in appetite and sleep patterns, having no interest in activities you once enjoyed, social isolation, feeling persistently sad or hopeless, and having a down mood on more days than not.

See the original post here:
Dealing with diabetes distress - Chicago Tribune

news

Cells behave differently when removed from their environments, just as cells that develop in cultures do not behave like cells in living creatures.

To study the effects of Alzheimers disease in a more natural environment, scientists from the lab of Professor Bart De Strooper (VIB-KU Leuven, Dementia Research Institute-UK) in collaboration with scientists from ULB (Professors Pierre Vanderhaeghen and Jean-Pierre Brion) successfully circumscribed this challenge by transplanting human neural cells into mouse brains containing amyloid plaques, one of the hallmarks of Alzheimers disease.

The results of their research showed that, unlike mouse neurons, human neurons that developed in this environment were extremely susceptible to Alzheimers disease.

The study of the development of Alzheimers disease on a molecular level presents unique challenges, as neurons behave differently in vivo vs in vitro. Using mice as models presents useful insights, but mouse models never fully develop the disease, despite the fact that their brains and neurons share many similarities with those of humans.

A team of researchers has now transplanted human neurons into mouse brains which mimic some of the hallmarks of Alzheimers disease, including the presence of amyloid plaques. They found that, compared to mouse neurons, human neurons were much more sensitive to amyloid plaque pathology.

This novel model allows for a better characterisation of the disease processes that actually take place in the brain of human patients.

Much of the work was performed in close cooperation with Professor Pierre Vanderhaeghen (ULB-WELBIO, VIB-KULeuven), whose lab previously pioneered the technology to differentiate human pluripotent stem cells into neural cells in vitro, and then transplant them in the mouse brain, generating a human/mouse chimera.

Professor Bart De Strooper (VIB-KU Leuven, Dementia Research Institute-UK), We relied heavily on the insights and expertise of Pierre Vanderhaeghen and his lab to set up this new AD model.

With this novel experimental technique, we can study how different cell types in the human brain respond to the Alzheimer pathology, hopefully unravelling the link between amyloid and tau protein pathology which leads to neuron death and is the holy grail of current Alzheimers research.

Professor Pierre Vanderhaeghen (ULB-WELBIO and VIB), While many features of the brain are conserved between different species such as humans and mice, the human brain displays a number of characteristics, which make us what we are, as a species and as individuals. However, studying this human-specific part remains a big challenge in neuroscience. This study is exciting because it constitutes a first proof of principle that stem cell-based models of transplanted human neurons can be applied to study an important neurological disease.

Moving forward, Professor De Strooper and his team are already planning a screen to identify human genes that protect against cell death associated with Alzheimers disease.

Professor Bart De Strooper (VIB-KU Leuven, Dementia Research Institute-UK), Now that we are able to investigate the disease by observing human cells directly, we can make progress in this field of research at a considerably faster pace.

The eventual end goal of the screening is to identify new drug targets within human cells themselves, something that was never possible before.

A breakthrough in research is not the same as a breakthrough in medicine. The realizations of VIB researchers can form the basis of new therapies, but the development path still takes years. This can raise a lot of questions. For any questions about the research please email: [emailprotected] Everyone can submit questions concerning this and other medically-oriented research directly to VIB via this address.

View post:
Human neurons in mouse brains are more susceptible to Alzheimer's pathology - Drug Target Review